Wednesday, September 25, 2019
- 1:15pm-2:45pm
-
Measuring disease progression with neuroimaging in MSA-a systematic review
Neuroimaging · Les Muses Terrace, Level 3
- 1:15pm-2:45pm
-
Medical evaluation as gold standard to control iPrognosis application derived data for early Parkinson’s disease detection
Phenomenology and Clinical Assessment of Movement Disorders · Les Muses Terrace, Level 3
- 1:15pm-2:45pm
-
Metabolic network abnormalities in drug-naive Parkinson’s disease
Neuroimaging · Les Muses Terrace, Level 3
- 1:15pm-2:45pm
-
Metabolic Surgery in the adjuvant management of Parkinson’s Disease
Surgical Therapy · Les Muses Terrace, Level 3
- 1:15pm-2:45pm
-
MIBG myocardial scintigraphy identifies premotor PD/DLB during a negative DAT scan period
Non-Motor Symptoms · Agora 3 West, Level 3
- 1:15pm-2:45pm
-
Micro structural Changes in Substantia Nigra are associated with Severity of Parkinson’s Disease.
Neuroimaging · Les Muses Terrace, Level 3
- 1:15pm-2:45pm
-
Microglia as modulators of exosomal alpha-synuclein transmission
Physiology and Pathophysiology · Les Muses, Level 3
- 1:15pm-2:45pm
-
Midbrain Atrophy in Patients with Preclinical Progressive Supranuclear Palsy
Neuroimaging · Les Muses Terrace, Level 3
- 1:15pm-2:45pm
-
Mild Cognitive Impairment in Parkinson’s disease in South Indian population – Development of a test battery and assessment of prevalence and characteristics
Cognition and Cognitive Disorders · Agora 3 East, Level 3
- 1:15pm-2:45pm
-
Mild Cognitive Impairment in Young Onset Parkinson Disease
Cognition and Cognitive Disorders · Agora 3 East, Level 3
- «Previous Page
- 1
- …
- 36
- 37
- 38
- 39
- 40
- …
- 67
- Next Page»